The RApid Switch From 1st Generation Somatostatin Analogues to PaSireOtiDe In Acromegaly
Recruiting
Observational Study
Acromegaly
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 100 (estimated)
- Sponsor
- IRCCS San Raffaele · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This is an observational, retrospective, national multicenter study aimed to evaluate the impact and efficacy of Time To Switch (TTS) from first-line to second-line medical therapy in Acromegaly.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Adult men and women (age ≥ 18 years) affected by acromegaly, including those of childbearing age
* Patients inadequately controlled with first generation somatostatin analogues (GH ≥1 μg/L and IGF-1 \>1.3×ULN)
* Second line medical treatment (Pasireotide; Pegvisomant only; com…
Contacts